Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung disease

Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung disease

Bibliographic Details
Main Authors:	Yannick Allanore, Jerome Avouac, Omar Al Tabaa, Marion Thomas, Roba Ghossan, Alice Combier, Alexia Steelandt
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-02-01
Series:	RMD Open
Online Access:	https://rmdopen.bmj.com/content/9/1/e002832.full

Similar Items

Relevance of circulating Semaphorin 4A for rheumatoid arthritis response to treatment
by: Jérôme Avouac, et al.
Published: (2023-09-01)

Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease
by: Francisco León Román, et al.
Published: (2023-08-01)

Rituximab Versus Mycophenolate in the Treatment of Recalcitrant Connective Tissue Disease–Associated Interstitial Lung Disease
by: Lisa Zhu, et al.
Published: (2021-01-01)

Is Rituximab-Associated Hypogammaglobulinemia Always Linked to B-Cell Depletion?
by: Anthie Damianaki, et al.
Published: (2022-02-01)

Rituximab compared to intravenous cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the RECITAL RCT
by: Toby M Maher, et al.
Published: (2024-02-01)

Rituximab for the treatment of connective tissue disease–associated interstitial lung disease: A systematic review and meta-analysis
by: Linrui Xu, et al.
Published: (2022-10-01)

RITUXIMAB TREATMENT FOR INTERSTITIAL LUNG INJURY IN SCLERODERMA SYSTEMATICA
by: Lidia Petrovna Ananieva, et al.
Published: (2013-12-01)

The Efficacy and Safety of Rituximab in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Case Series
by: Youngeun Jang, et al.
Published: (2023-05-01)

Efficacy and Safety of Rituximab in Autoimmune Disease—Associated Interstitial Lung Disease: A Prospective Cohort Study
by: Natalia Mena-Vázquez, et al.
Published: (2022-02-01)

Factors associated with rituximab-mediated B cell depletion in ABO-incompatible adult living donor liver transplantation
by: Suk Kyun Hong, et al.
Published: (2023-09-01)

Rituximab treatment in patients with systemic sclerosis and interstitial lung disease
by: Abdel Gaffar A Mohammed, et al.
Published: (2017-01-01)

A rare case of rituximab induced interstitial lung disease
by: Kamal Kant Sahu, et al.
Published: (2016-01-01)

Connective tissue disease-associated interstitial lung disease
by: Karin Mueller Storrer, et al.
Published: (2024-03-01)

B-cell depletion and primary Sjögren’s syndrome: is there a role for rituximab?
by: P. Sarzi-Puttini, et al.
Published: (2011-06-01)

Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review
by: Belén Atienza-Mateo, et al.
Published: (2020-09-01)

Genetics and pathogenesis of connective tissue disease-associated interstitial lung disease
by: Sharath Kumar
Published: (2021-01-01)

Lung transplantation in connective tissue disease associated interstitial lung disease
by: Srinivas Rajagopala, et al.
Published: (2021-01-01)

Rituximab-induced interstitial pneumonitis in patient with non-Hodgkin lymphoma: a clinical case
by: Nikolai A. Ognerubov, et al.
Published: (2022-08-01)

Management perspectives from patients with fibromyalgia experiences with the healthcare pathway: a qualitative study
by: Alexandra Kachaner, et al.
Published: (2023-12-01)

The Role of the Microbiome in Connective-Tissue-Associated Interstitial Lung Disease and Pulmonary Vasculitis
by: Fotios Drakopanagiotakis, et al.
Published: (2022-12-01)

The Role of Lung Colonization in Connective Tissue Disease-Associated Interstitial Lung Disease
by: Alberto Ricci, et al.
Published: (2021-04-01)

SLE‐associated myelitis successfully treated by rituximab
by: Alireza Khabbazi, et al.
Published: (2022-11-01)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
by: Toby M Maher, et al.
Published: (2023-02-01)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
by: Anam Tariq, et al.
Published: (2022-04-01)

Rituximab for treatment-resistant schizophrenia and/or obsessive-compulsive disorder (OCD): functional connectivity and cytokines associated with symptomatic improvements
by: M. B. Humble, et al.
Published: (2023-03-01)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
by: Jones, R, et al.
Published: (2010)

Is rituximab effective for induction of remission in ANCA-associated vasculitis?
by: Carmen Rain, et al.
Published: (2015-08-01)

The role of rituximab in the treatment of ANCA-associated vasculitides (AAV)
by: Thomas Daikeler, et al.
Published: (2015-01-01)

Rituximab treatment in a case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failure
by: Zappa Maria, et al.
Published: (2011-08-01)

Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease
by: Jean Paul Higuero Sevilla, et al.
Published: (2023-07-01)

Retraction Note: Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis
by: Nadira Ruzehaji, et al.
Published: (2023-11-01)

Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial
by: Shervin Assassi, et al.
Published: (2022-10-01)

P06 OFATUMUMAB FOR B CELL DEPLETION THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO ARE INTOLERANT OF RITUXIMAB
by: S. McAdoo, et al.
Published: (2016-11-01)

THE IMPORTANCE OF HIGH-RESOLUTION COMPUTED TOMOGRAPHY IN EVALUATING THE EFFICACY OF RITUXIMAB IN PATIENTS WITH INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS
by: O. A. Koneva, et al.
Published: (2018-11-01)

Editorial: Advances in understanding the pathogenesis of and designing therapies for connective tissue disease-associated interstitial lung disease
by: Lihua Duan, et al.
Published: (2023-10-01)

Correction: Learnings from clinical trials in patients with connective tissue disease‑associated interstitial lung disease
by: Jean Paul Higuero Sevilla, et al.
Published: (2023-07-01)

Sustained CD19+CD27+ Memory B Cell Depletion after Rituximab Treatment in Patients with Pemphigus Vulgaris
by: Katharina Boch, et al.
Published: (2022-03-01)

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
by: Flossmann, O, et al.
Published: (2006)

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
by: Guerry, M, et al.
Published: (2012)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
by: Mohammad Amin Habibi, et al.
Published: (2022-12-01)